Answers are grounded in this paper and cite their sources.
OBJECTIVES: We aimed to characterize clinical and autoantibody profiles associated with cardiac involvement and to develop a practical risk-stratification model for identifying IIM patients at increased cardiac risk. METHODS: A total of 220 patients were enrolled, including 55 with cardiac involvement and 165 without. Clinical, serological, and laboratory characteristics were compared. Three nested multivariable logistic regression models assessed the incremental value of hs-cTnT and hs-cTnI, and the final model was developed into a nomogram and evaluated by ROC analysis, calibration, and decision curve analysis. RESULTS: Patients with cardiac involvement showed more severe muscle manifestations and dysphagia, accompanied by greater systemic inflammation and distinct autoantibody profiles. hs-cTnT showed high sensitivity but substantial associations with skeletal muscle injury, whereas hs-cTnI was more specific with weaker correlations. An hs-cTnI-based nomogram integrating interstitial lung disease, albumin, high-density lipoprotein cholesterol, and lactate dehydrogenase demonstrated excellent discrimination, good calibration, and favorable clinical utility. CONCLUSION: Cardiac involvement in IIM is characterized by a clinically heterogeneous phenotype in which severe myopathy and dysphagia may be more prominent than typical cardiac symptoms. Our hs-cTnI-based nomogram may serve as an initial risk-stratification and triage tool to identify patients who warrant closer cardiac evaluation, including targeted cardiac magnetic resonance imaging.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: